Bioactivation of 3-n-butylphthalide via sulfation of its major metabolite 3-hydroxy-NBP: Mediated mainly by sulfotransferase 1A1

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 774-781

  Diao, Xingxing ^a   Pang, Xiaoyan ^a   Xie, Cen ^a   Guo, Zitao ^a   Zhong, Dafang ^a   Chen, Xiaoyan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 BUTYLPHTHALIDE; DRUG METABOLITE; GLUTATHIONE; PHTHALIDE DERIVATIVE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFOTRANSFERASE 1A1;

ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CATALYSIS; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SULFATION; DRUG URINE LEVEL; ELECTROPHILICITY; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; LIVER CELL; LIVER CYTOSOL; LIVER HOMOGENATE; LIVER MICROSOME; LIVER TOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT;

ACETYLCYSTEINE; ANIMALS; ARYLSULFOTRANSFERASE; BENZOFURANS; BIOTRANSFORMATION; CELL SURVIVAL; CELLS, CULTURED; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HEPATOCYTES; HUMANS; HYDROXYLATION; KIDNEY; LIVER; MALE; MICROSOMES, LIVER; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SULFUR COMPOUNDS;

EID: 84896130060     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056218     Document Type: Article

References (42)

1. Bjorge SM and Baillie TA (1991) Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab Dispos 19:823-829.
2. Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, and Weinshilboum RM (2001) Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11:57-68. (Pubitemid 32108662)
3. Chong ZZ and Feng YP (1999) dl-3-n-Butylphthalide improves regional cerebral blood flow after experimental subarachnoid hemorrhage in rats. Zhongguo Yao Li Xue Bao 20:509-512.
4. Clapp JJ and Young L (1970) Formation of mercapturic acids in rats after the administration of aralkyl esters. Biochem J 118:765-771.
5. Coughtrie MWH, Sharp S, Maxwell K, and Innes NP (1998) Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. Chem Biol Interact 109:3-27. (Pubitemid 28161098)
6. Cui L, Li S, Zhang W, Peng G, He L, Fan D, Shen Y, Wang Y, Gao X, and Jia J, et al. (2008) Effects of dl-3-butylphthalide soft capsules on treatment of acute ischemic stroke: multi-center, randomized, double-blind, double-dummy and aspirin-control study [in Chinese]. Zhonghua Shen Jing Ge Za Zhi 41:727-730.
7. Cui L, Liu X, Zhu Y, Fan D, Xie R, Shen Y, Zhang W, Yang X, Ha Z, and Li L, et al. (2005) Effects of dl-3-butylphthalide on treatment of acute ischemic stroke with moderate symptoms: a multi-center, randomized, double-blind, placebo-control trial [in Chinese]. Zhonghua Shen Jing Ge Za Zhi 38:251-254. (Pubitemid 40966363)
8. Cui LY, Zhu YC, Gao S, Wang JM, Peng B, Ni J, Zhou LX, He J, and Ma XQ (2013) Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: a randomized, double-blind trial. Chin Med J (Engl) 126:3405-3410.
9. Dasaradhi L and Shibutani S (1997) Identification of tamoxifen-DNA adducts formed by alphasulfate tamoxifen and alpha-acetoxytamoxifen. Chem Res Toxicol 10:189-196. (Pubitemid 27091887)
10. Diao X, Deng P, Xie C, Li X, Zhong D, Zhang Y, and Chen X (2013a) Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos 41:430-444.
11. Diao X, Ma Z, Wang H, Zhong D, Zhang Y, Jin J, Fan Y, and Chen X (2013b) Simultaneous quantitation of 3-n-butylphthalide (NBP) and its four major metabolites in human plasma by LC-MS/MS using deuterated internal standards. J Pharm Biomed Anal 78-79:19-26.
12. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22. (Pubitemid 43264722)
13. Glatt H (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129:141-170.
14. Gong J, Gan J, and Iyer RA (2012) Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib. Drug Metab Dispos 40:219-226.
15. Gopaul SV, Farrell K, and Abbott FS (2000) Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos 28:823-832. (Pubitemid 30470833)
16. Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, Ikeda T, and Yamazoe Y (2002) Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949. (Pubitemid 34815426)
17. Hosomi H, Fukami T, Iwamura A, Nakajima M, and Yokoi T (2011) Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos 39:1388-1395.
18. Iwamura A, Fukami T, Hosomi H, Nakajima M, and Yokoi T (2011) CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos 39:838-846.
19. Kim SY, Laxmi YR, Suzuki N, Ogura K, Watabe T, Duffel MW, and Shibutani S (2005) Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers. Drug Metab Dispos 33:1673-1678. (Pubitemid 41539966)
20. Mohamed LA and Kaddoumi A (2013) In vitro investigation of amyloid-β hepatobiliary disposition in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos 41:1787-1796.
21. Mulder GJ and Scholtens E (1977) Phenol sulphotransferase and uridine diphosphate glucuronyltransferase from rat liver in vivo and vitro. 2,6-Dichloro-4-nitrophenol as selective inhibitor of sulphation. Biochem J 165:553-559. (Pubitemid 8165062)
22. Nagar S, Walther S, and Blanchard RL (2006) Sulfotransferase (SULT) 1A1 polymorphic variants*1,*2, and*3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol 69:2084-2092. (Pubitemid 43894328)
23. NBP Pharmaceutical (2009) Butylphthalide soft capsules package insert.
24. Peng Y, Xing C, Lemere CA, Chen G, Wang L, Feng Y, and Wang X (2008) l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci Lett 434:224-229.
25. Poon GK, Chen Q, Teffera Y, Ngui JS, Griffin PR, Braun MP, Doss GA, Freeden C, Stearns RA, and Evans DC, et al. (2001) Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab Dispos 29 :1608-1613. (Pubitemid 33111594)
26. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, and Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298-304. (Pubitemid 27480360)
27. Renner G and Nguyen PT (1984) Mechanisms of the reductive denitration of pentachloronitrobenzene (PCNB) and the reductive dechlorination of hexachlorobenzene (HCB). Xenobiotica 14 : 705-710. (Pubitemid 15200400)
28. Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab Dispos 37:2255-2261.
29. Rinaldi R, Eliasson E, Swedmark S, and Morgenstern R (2002) Reactive intermediates and the dynamics of glutathione transferases. Drug Metab Dispos 30:1053-1058.
30. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29-83.
31. Sharma AM, Klarskov K, and Uetrecht J (2013) Nevirapine bioactivation and covalent binding in the skin. Chem Res Toxicol 26:410-421.
32. Shukla U, Tumma N, Gratsch T, Dombkowski A, and Novak RF (2013) Insights into insulin-mediated regulation of CYP2E1: miR-132/-212 targeting of CYP2E1 and role of phosphatidylinositol 3-kinase, Akt (protein kinase B), mammalian target of rapamycin signaling in regulating miR-132/-212 and miR-122/-181a expression in primary cultured rat hepatocytes. Drug Metab Dispos 41:1769-1777.
33. Walle T, Eaton EA, and Walle UK (1995) Quercetin, a potent and specific inhibitor of the human P-form phenosulfotransferase. Biochem Pharmacol 50:731-734.
34. Wang L, Raghavan N, He K, Luettgen JM, Humphreys WG, Knabb RM, Pinto DJ, and Zhang D (2009) Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 37:802-808.
35. Wang LQ and James MO (2006) Inhibition of sulfotransferases by xenobiotics. Curr Drug Metab 7:83-104.
36. Weinshilboum RM (1986) Phenol sulfotransferase in humans: properties, regulation, and function. Fed Proc 45:2223-2228.
37. Weinshilboum RM, Otterness DM, Aksoy IA, Wood TC, Her C, and Raftogianis RB (1997) Sulfation and sulfotransferases 1: sulfotransferase molecular biology: cDNAs and genes. FASEB J 11:3-14. (Pubitemid 27076319)
38. Xie C, Zhou JL, Guo ZT, Diao XX, Gao ZW, Zhong DF, Jiang HY, Zhang LJ, and Chen XY (2013) Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 168:1687-1706.
39. Xu B and Zhao Z (2011) Butylphthalide injection, an innovative drug originated in China for the treatment of ischemic stroke [in Chinese]. Chin J New Drugs 20:947-950.
40. Yalcin EB, More V, Neira KL, Lu ZJ, Cherrington NJ, Slitt AL, and King RS (2013) Down-regulation of sulfotransferase expression and activity in diseased human livers. Drug Metab Dispos 41:1642-1650.
41. Yan CH, Feng YP, and Zhang JT (1998) Effects of dl-3-n-butylphthalide on regional cerebral blood flow in right middle cerebral artery occlusion rats. Zhongguo Yao Li Xue Bao 19:117-120. (Pubitemid 28123545)
42. Yang H, Hu GY, Chen J, Wang Y, and Wang ZH (2007) Synthesis, resolution, and antiplatelet activity of 3-substituted 1(3H)-isobenzofuranone. Bioorg Med Chem Lett 17:5210-5213. (Pubitemid 47260736)